Rocket Pharmaceuticals is trading at $2.84 (-5.96%) as biotechnology and risk assets weaken broadly.
- XBI is down 2.04%, while the Nasdaq is down 0.80%, pressuring growth-oriented biotech stocks.
- Rising Treasury yields and inflation concerns are weighing on risk appetite.
- No fresh company-specific announcement was identified; the latest major company update was September 15 FDA trial alignment.